Yonsei University

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Private

Established: 1885-01-01

Employees: 5K

Market Cap: -

Website: http://www.yonsei.ac.kr

Clinical Trials

Articulated Laparoscopic Instruments Clinical Study

Recruiting

Conditions: Gastric Cancer

Interventions: Device: Minimally Invasive Surgery

First Posted Date: 2022-09-22

Last Posted Date: 2022-10-03

Lead Sponsor: Yonsei University

Target Recruit Count: 1155

Registration Number: NCT05550974

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Demonstration Study of the Effect of the Transcranial Direct Current Stimulation (tDCS) on Depressed Patients

Not Applicable

Recruiting

Conditions: Depression

Interventions: Device: transcranial direct current stimulation (tDCS)

First Posted Date: 2022-09-14

Last Posted Date: 2023-01-26

Lead Sponsor: Yonsei University

Target Recruit Count: 198

Registration Number: NCT05539131

Locations: 🇰🇷
Yongin Severance Hospital, Yonsei University College of Medicine, Yongin, Gyeonggi, Korea, Republic of
🇰🇷
National Health Insurance Service Ilsanhospital, Goyang, Gyeonggi, Korea, Republic of
🇰🇷
Myongji Hospital, Goyang, Gyeonggi, Korea, Republic of

and more 2 locations

Precision Treatment With Angiotensin Converting Enzyme Inhibitor

Phase 4

Completed

Conditions: Hypertension

Interventions: Drug: genotyping and selection of renin-angiotensin system blocker
Drug: Perindopril

First Posted Date: 2022-09-10

Last Posted Date: 2023-01-11

Lead Sponsor: Yonsei University

Target Recruit Count: 77

Registration Number: NCT05535595

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Phase Ib/II Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With Paclitaxel in Epstein-Barr Virus(EBV)-Related, or Microsatellite Instability-High (MSI-H), or Programmed Cell Death Ligand 1 (PD-L1) Positive Advanced Gastric Cancer

Phase 1

Completed

Conditions: Recurrent/Metastatic Gastric Cancer

Interventions: Drug: Nivolumab, Paclitaxel

First Posted Date: 2022-09-10

Last Posted Date: 2022-09-10

Lead Sponsor: Yonsei University

Target Recruit Count: 50

Registration Number: NCT05535569

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Comparison of the Electric Plasma Surgical Tool "PlasmaBlade" for Replacement of the Deep Brain Stimulation (DBS) Devices With Conventional Surgery

Recruiting

Conditions: Essential Tremor
Epilepsy
Parkinson Disease
Dystonia

First Posted Date: 2022-09-10

Last Posted Date: 2022-09-10

Lead Sponsor: Yonsei University

Target Recruit Count: 50

Registration Number: NCT05535556

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Fibroblast Growth Factor (FGFs) / Fibroblast Growth Factor Receptor (FGFRs) Genetic as a Second-line Therapy for Recurrent / Progressive Gastric Cancer With INCB054828 and Paclitaxel a Study to Evaluate the Safety and Efficacy of Combination Therapy.

Phase 1

Completed

Conditions: Fibroblast Growth Factors (FGFs)/Fibroblast Growth Factor Receptors (FGFRs) Genetic Aberration Gastric Cancer, INCB054828, Paclitaxel

Interventions: Drug: INCB054828, Paclitaxel

First Posted Date: 2022-09-07

Last Posted Date: 2024-05-08

Lead Sponsor: Yonsei University

Target Recruit Count: 15

Registration Number: NCT05529667

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Gemcitabine With Oxaliplatin (GEMOX) in Patients With Advanced Hepatocellular Carcinoma After Failure of Sorafenib Treatment

Phase 2

Completed

Conditions: Hepatocellular Carcinoma, Unresectable, Advanced

Interventions: Drug: Gemcitabine, Oxaliplatin

First Posted Date: 2022-08-26

Last Posted Date: 2022-08-26

Lead Sponsor: Yonsei University

Target Recruit Count: 32

Registration Number: NCT05517239

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Efficacy of Triplet Combination With Pembrolizumab, Neratinib, and Paclitaxel as a Second Line Treatment in Recurrent/Advanced Gastric Cancer Having Somatic Human Epidermal Growth Factor Receptor Family (EGFR, HER2, HER3, HER4) Mutations or HER2 Amplification/Overexpression

Phase 2

Withdrawn

Conditions: Recurrent/Advanced Gastric Cancer

Interventions: Drug: Chemotherapy

First Posted Date: 2022-08-23

Last Posted Date: 2023-06-15

Lead Sponsor: Yonsei University

Registration Number: NCT05512182

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

Phase II Study of Pembrolizumab (Keytruda®) and Trifluridine/Tipiracil (Lonsurf®) With Previously Treated Advanced Gastric Cancer

Phase 1

Not yet recruiting

Conditions: Gastric and Gastroesophageal Junction Adenocarcinoma

Interventions: Drug: Pembrolizumab (Keytruda®), Trifluridine/Tipiracil (Lonsurf®)

First Posted Date: 2022-08-19

Last Posted Date: 2022-08-19

Lead Sponsor: Yonsei University

Target Recruit Count: 75

Registration Number: NCT05508737

Detection of Tumor DNA Through Cervical Smear and Liquid Biopsy in Endometrial Cancer Patients and Evaluation of Prognostic and Predictive Values of Tumor DNA Assay

Conditions: Endometrial Cancer

First Posted Date: 2022-08-17

Last Posted Date: 2022-08-17

Lead Sponsor: Yonsei University

Target Recruit Count: 300

Registration Number: NCT05504161

Locations: 🇰🇷
Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy